Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
MedAdvisor Ltd is engaged in the development and deployment of the MedAdvisor medication and adherence platform. The MedAdvisor platform is focused on improving health outcomes by connecting health professionals with their patients using mobile and web technologies. It has five reporting segments: MedAdvisor; USA, UK, and Asia, and corporate. The company derives most of its revenues from MedAdvisor.
|22 Oct 2021||$0.37||$0.04||12.12%||1,705,371||$0.34||$0.39||$0.33|
|21 Oct 2021||$0.33||$0.00||0.00%||118,748||$0.34||$0.34||$0.32|
|20 Oct 2021||$0.33||$0.02||6.35%||202,338||$0.32||$0.33||$0.32|
|19 Oct 2021||$0.32||$0.02||6.67%||222,966||$0.31||$0.32||$0.31|
|18 Oct 2021||$0.30||$0.00||0.00%||572,738||$0.29||$0.30||$0.29|
|15 Oct 2021||$0.30||$-0.02||-6.25%||250,972||$0.32||$0.32||$0.30|
|14 Oct 2021||$0.32||$0.00||0.00%||44,994||$0.32||$0.33||$0.32|
|13 Oct 2021||$0.32||$0.00||0.00%||304,047||$0.31||$0.33||$0.31|
|12 Oct 2021||$0.32||$-0.01||-3.08%||27,443||$0.31||$0.32||$0.31|
|11 Oct 2021||$0.33||$0.02||6.56%||2,080||$0.31||$0.33||$0.31|
|08 Oct 2021||$0.31||$0.01||3.33%||235,812||$0.31||$0.32||$0.30|
|07 Oct 2021||$0.30||$0.02||7.02%||290,699||$0.31||$0.31||$0.29|
|06 Oct 2021||$0.29||$-0.01||-3.39%||610,583||$0.30||$0.30||$0.29|
|05 Oct 2021||$0.30||$0.00||0.00%||268,485||$0.29||$0.30||$0.29|
|04 Oct 2021||$0.30||$-0.01||-3.33%||6,126||$0.31||$0.31||$0.30|
|01 Oct 2021||$0.30||$0.00||0.00%||212,590||$0.30||$0.30||$0.30|
|30 Sep 2021||$0.30||$-0.01||-3.28%||93,276||$0.31||$0.31||$0.30|
|29 Sep 2021||$0.31||$-0.01||-3.23%||66,773||$0.30||$0.31||$0.30|
|28 Sep 2021||$0.31||$0.00||0.00%||1,789,477||$0.30||$0.31||$0.30|
|27 Sep 2021||$0.31||$0.00||0.00%||234,851||$0.31||$0.31||$0.31|
|24 Sep 2021||$0.31||$0.01||3.33%||269,026||$0.31||$0.32||$0.31|
|23 Sep 2021||$0.30||$0.01||3.39%||240,679||$0.30||$0.30||$0.30|
|22 Dec 2020||Chris Ridd||Issued||184||$70,000||
Issue of securities.
|22 Dec 2020||Chris Ridd||Issued||1||$2||
Issue of options.
|22 Dec 2020||Robert Read||Issued||4||$3,150||
Issue of options.
|18 Nov 2020||Joshua Swinnerton||Issued||526||$200,000||
|18 Nov 2020||Sandra Hook||Issued||71||$27,142||
|18 Nov 2020||Robert Read||Issued||70||$26,600||
|Mr Chris David Ridd||Non-Executive ChairmanNon-Executive Director||Feb 2020||
Mr Ridd has 30 years experience in the IT industry including 5 years as Managing Director for Xero Australia and 15 years at Microsoft in senior executive roles. He led Xero's expansion in the Australian market from a startup to become the online cloud accounting software company.
|Mr Robert Read||Chief Executive OfficerManaging Director||Nov 2015||
Mr Read has experience in a range of businesses, including Director of Strategy and Operations in one of the world's pharmaceutical companies, GSK and roles in venture capital and private equity. He has had roles in business consultancy and senior roles in private equity including Director at ANZ Private Equity and Managing Director at Harbert Private Equity, specialising in growth of small and medium sized businesses. He brings a range of skills to the position of CEO - including leadership, sales and marketing, financial performance improvement and a understanding of the requirements to grow businesses. He is a member of Risk and People Committee.
|Mr Jim Xenos||Non-Executive Director||Nov 2015||
Mr Xenos brings to the board pharmaceuticals industry experience and market insight and forge over 25 years and have lead teams to drive outcomes. He has a record of delivering market share across national and multinational corporations by creating brand and portfolio strategies, and by introducing new product offerings that leverage go-to market platforms in industry categories. He is a member of the Risk and People Committee.
|Mr Joshua Swinnerton||CTOExecutive Director||Nov 2015||
Mr Swinnerton has experience and manage sizeable IT ventures, as a consultant, and as the technical and Operation lead of start-up companies. He led a technology start-up which he also founded and sold into the US as well as raising funds in the US for the company's expansion and managed software development. During this time he gained experience in bridging the gap between technology and business objectives.
|Mr Peter Duncombe Bennetto||Non-Executive Director||Nov 2013||
Mr Bennetto is an experienced company director, with skills in banking, corporate finance and governance. He has held company director positions in exploration, mining and manufacturing companies listed on the ASX since 1990. Mr Bennetto has been Non-Executive Chairman at MedAdvisor Limited (formerly Exalt Resources Limited) since November 28, 2013. Mr Bennetto is currently non-executive Chairman of Ironbark Zinc Ltd and Kingwest Resources Ltd. He is a member of the Risk and People Committee.
|Ms Sandra Margaret Hook||Non-Executive Director||Jan 2016||
Ms Hook has over 25 years experience which include development and implementing business and brands to drive change. She has a record in delivering customer business transformation and transitioning organisations in evolving environments. She brings financial management experience of her career which includes CEO, COO, GM, Marketing Director and Snr Brand Manager with some of Australia's media companies including News Limited, Foxtel, Federal Publishing Company, Murdoch Magazines and Fairfax. She brings a focus on customer digital innovation at Board level. Since 2000 she has served as a non-executive director on listed, public and private companies, and government bodies. She is a trustee of the Sydney Harbour Federation Trust. She is Chair of Risk Committee and a member of People Committee.
|Mr Lucas Merrow||Non-Executive Director||Aug 2021||
Mr Merrow has experience in building Medtech enterprises, including Cotiviti/HMS-owned Eliza and the now MedAdvisor-owned Adheris. Having co-founded the MedAdvisor-owned Adheris in 1991, Merrow helped Adheris to grow a pharmacy network in the US with patient access, allowing Adheris to build a blue-chip customer base of many of the world's pharma companies. After Adheris, Mr Merrow cofounded Eliza Corporation which focusing on patient engagement and behaviour change on behalf of health insurers in the US.
|Ms Naomi Lawrie||General CounselCompany Secretary||Aug 2020||
|Simon Glover||Chief Financial Officer||
|Steve Watt||Chief Revenue Officer||
|Ruba El Afifi||EGM People and Culture||
|Naomi Lawrie||General CounselCompany Secretary||
|Craig Schnuriger||Interim Chief Technology Officer||
|Health Management Systems Inc||31,428,571||12.74%|
|Ebos Ph Pty Ltd||26,459,627||10.72%|
|Kojent Pty Ltd <Kojent A/C>||20,540,866||8.33%|
|HSBC Custody Nominees (Australia) Limited||16,441,606||6.66%|
|Wavey Industries Pty Ltd <Josh Swinnerton Family A/C>||15,008,943||6.08%|
|Regal Funds Management Pty Ltd||14,981,247||6.07%|
|Romida Enterprises Pty Ltd <Romida Family A/C>||12,992,910||5.27%|
|J P Morgan Nominees Australia Pty Limited||11,856,538||4.81%|
|Sigma Company Limited||5,952,381||2.41%|
|Provare Pty Ltd <Provare Investment A/C>||3,419,970||1.39%|
|Mishra Enterprises Pty Ltd <Mishra Family A/C>||2,894,737||1.17%|
|Gread Management Pty Limited <The A G & R R Family A/C>||2,631,983||1.07%|
|Citicorp Nominees Pty Limited||2,424,829||0.98%|
|HSBC Custody Nominees (Australia) Limited A/C 2||2,238,097||0.91%|
|Ethan Allen Investments Pty Ltd <Ethan Allen Invest Unit A/C>||2,000,000||0.81%|
|Dr Christopher Harold Benton||2,000,000||0.81%|
|National Nominees Limited||1,942,664||0.79%|
|Capital Concerns Pty Limited cLogue Family Super Fund A/C>||1,855,344||0.75%|
|Canonbar Investments Pty Ltd||1,568,964||0.64%|
|Mr Hamish John Hepburn||1,499,999||0.61%|